Xesai / iStockphoto.com
US-based Catalent, which provides delivery technologies for drugs, has agreed to buy Juniper Pharmaceuticals for $133 million.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Catalent, Juniper Pharmaceuticals, mergers and acquisitions, Crinone, drug development